- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Generalised myasthenia gravis (gMG)
- Meeting Date: July 2024
- Public Summary Document (PSD) July 2024 PBAC Meeting - (PDF 938KB)
- Public Summary Document (PSD) July 2024 PBAC Meeting - (Word 234KB)
Ravulizumab – July 2024
Ravulizumab; Solution concentrate for I.V. infusion 300 mg in 3 mL, Solution concentrate for I.V. infusion 1,100 mg in 11 mL; Ultomiris®
Last updated
30 May 2025